Follow
Joaquim Bellmunt
Joaquim Bellmunt
Associate Professor of Medicine Harvard Medical School
Verified email at dfci.harvard.edu
Title
Cited by
Cited by
Year
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease
A Heidenreich, J Bellmunt, M Bolla, S Joniau, M Mason, V Matveev, ...
European urology 59 (1), 61-71, 2011
5450*2011
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm …
JE Rosenberg, J Hoffman-Censits, T Powles, MS Van Der Heijden, ...
The Lancet 387 (10031), 1909-1920, 2016
37092016
EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent
N Mottet, J Bellmunt, M Bolla, E Briers, MG Cumberbatch, M De Santis, ...
European urology 71 (4), 618-629, 2017
36442017
Pembrolizumab as second-line therapy for advanced urothelial carcinoma
J Bellmunt, R De Wit, DJ Vaughn, Y Fradet, JL Lee, L Fong, NJ Vogelzang, ...
New England Journal of Medicine 376 (11), 1015-1026, 2017
31862017
Early childhood development coming of age: science through the life course
MM Black, SP Walker, LCH Fernald, CT Andersen, AM DiGirolamo, C Lu, ...
The Lancet 389 (10064), 77-90, 2017
27252017
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
T Powles, JP Eder, GD Fine, FS Braiteh, Y Loriot, C Cruz, J Bellmunt, ...
Nature 515 (7528), 558-562, 2014
25962014
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent—update 2013
A Heidenreich, PJ Bastian, J Bellmunt, M Bolla, S Joniau, T van der Kwast, ...
European urology 65 (1), 124-137, 2014
24392014
Comprehensive molecular characterization of muscle-invasive bladder cancer
AG Robertson, J Kim, H Al-Ahmadie, J Bellmunt, G Guo, AD Cherniack, ...
Cell 171 (3), 540-556. e25, 2017
22242017
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
AV Balar, MD Galsky, JE Rosenberg, T Powles, DP Petrylak, J Bellmunt, ...
The Lancet 389 (10064), 67-76, 2017
20882017
EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer
P Cornford, J Bellmunt, M Bolla, E Briers, M De Santis, T Gross, AM Henry, ...
European urology 71 (4), 630-642, 2017
15552017
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase …
AV Balar, D Castellano, PH O'Donnell, P Grivas, J Vuky, T Powles, ...
The Lancet Oncology 18 (11), 1483-1492, 2017
12442017
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival
B Escudier, J Bellmunt, S Négrier, E Bajetta, B Melichar, S Bracarda, ...
J Clin Oncol 28 (13), 2144-50, 2010
10532010
Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma
T Powles, SH Park, E Voog, C Caserta, BP Valderrama, H Gurney, ...
New England Journal of Medicine 383 (13), 1218-1230, 2020
10182020
A consensus molecular classification of muscle-invasive bladder cancer
A Kamoun, A de Reyniès, Y Allory, G Sjödahl, AG Robertson, R Seiler, ...
European urology 77 (4), 420-433, 2020
9462020
Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell …
J Bellmunt, C Théodore, T Demkov, B Komyakov, L Sengelov, ...
J Clin Oncol 27 (27), 4454-4461, 2009
8572009
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with …
P Dombernowsky, I Smith, G Falkson, R Leonard, L Panasci, J Bellmunt, ...
Journal of clinical oncology 16 (2), 453-461, 1998
8181998
Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin …
M De Santis, J Bellmunt, G Mead, JM Kerst, M Leahy, P Maroto, T Gil, ...
Journal of clinical oncology 30 (2), 191, 2012
7562012
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer
N Mottet, J Bellmunt, M Bolla, S Joniau, M Mason, V Matveev, HP Schmid, ...
Actas Urológicas Españolas (English Edition) 35 (10), 565-579, 2011
7342011
Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy
MD Galsky, NM Hahn, J Rosenberg, G Sonpavde, T Hutson, WK Oh, ...
Journal of Clinical Oncology 29 (17), 2432-2438, 2011
6122011
Guidelines on prostate cancer
N Mottet, J Bellmunt, E Briers, RCN Van den Bergh, M Bolla, ...
European Association of Urology 56, e137, 2015
5852015
The system can't perform the operation now. Try again later.
Articles 1–20